BEIJING, Sept. 30, 2020 /PRNewswire/ -- Concord
Medical Services Holdings Limited ("Concord Medical" or the
"Company") (NYSE: CCM), a healthcare provider specializing in
cancer care, research and prevention by operating a network of
medically advanced comprehensive cancer hospitals and standalone
radiotherapy and diagnostic imaging centers in China,
today announced that the hoisting ceremony for the proton therapy
system of Guangzhou Concord Cancer Center (the
"Center") was held at the construction site on September
30, 2020.
Proton therapy technology is able to be used to treat certain
types of cancers, such as cancers near optical nerves, the spinal
cord or central nervous system and in the head and neck area, as
well as prostate cancer and cancer in pediatric cases, and limit
the damage to surrounding tissues to an acceptable level, as
compared to the conventional radiotherapy. Proton therapy
technology has been substantially examined and applied in
the United States. Meizhong Jiahe
Hospital Management Group Co., Ltd, the Company's subsidiary, is
endeavored to focus on the R&D of proton therapy technology and
to contribute to the international development of proton therapy,
especially for the treatment of those more commonly diagnosed
cancers in Chinese patients, such as nasopharyngeal carcinoma, lung
cancer, liver cancer, breast cancer and pediatric tumors. The
Company will form an advanced cancer treatment technologies R&D
and application center with characteristics of proton therapy
technologies covering China and
even Southeast Asia.
Dr. Jianyu Yang, Chairman and Chief Executive Officer
of Concord Medical, commented, "I am pleased to see that,
after years of efforts, the Center has started the installation of
proton therapy system (the "System"). The hoisting of the System of
the Center is an important milestone in the overall strategic
development of Concord Medical. We will make every effort to
ensure that the project is completed on time, with emphasis on
quality and safety. I believe that the completion of
the System at the Center will not only promote the development
of cancer radiotherapy in China, but will also help Chinese
cancer patients in their recovery too."
"We are very excited to have achieved this important milestone
by overcoming uncertainties in the COVID-19 pandemic," said Dr.
Xiao Zhang, Senior Vice President
and President of Varian Greater China Region, "Concord Medical is
dedicated to providing quality cancer care services to Chinese
patients. Once completed, it will be one of the leading cancer
centers equipped with proton therapy in Southern China. We are very committed to the
partnership with Concord Medical to provide the advanced cancer
care for the benefit of patients in the greater region."
The Center is a comprehensive cancer hospital established by the
Company in cooperation with the Sun Yat-sen University Cancer
Center, and is the first batch of high-tech projects launched by
Sino-Singapore Guangzhou Knowledge City (the "SSGKC Project"). The
SSGKC Project is located in the center of the golden triangle in
Guangdong-Hong Kong-Macao Greater
Bay Area. It covers the major cities of the Pearl River Delta,
Hong Kong and Macao by car in two hours. The Center has
goals to establish a "five in one" international cancer center with
clinical diagnosis and treatment, cancer prevention, medical
research, specialist training and remote consultation in
Guangzhou. The Center covers a
gross floor area of 40,000 square meters, and has 400 patient beds.
The Center equips with Varian's ProBeam proton therapy system to
provide high quality and humanized cancer treatment services for
patients in China or abroad.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare
provider specializing in cancer care, research and prevention. The
Company operates a network of medically advanced comprehensive
cancer hospitals and standalone radiotherapy and diagnostic imaging
centres in China. The Company
focuses on providing multidisciplinary cancer care approach in all
areas of oncology services in its cancer hospitals. The Company
also equips its hospitals with technologically advanced equipment
such as the state-of-the-art proton therapy system in its
Beijing, Shanghai and Guangzhou cancer hospitals. As of June 30, 2020, the Company operated a network of
27 centers based in 20 hospitals, spanning over 20 cities across 13
provinces and administrative regions in China. To ensure the commitment to the highest
level of clinical care for patients, the Company offers ongoing
education and training for doctors and other medical professionals
in its network hospitals and centres in both local and overseas
medical institutions. For more information, please see
http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements. These
forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar expressions.
Forward-looking statements are inherently subject to uncertainties
and contingencies beyond the Company's control and based upon
premises with respect to future business decisions, which are
subject to change. A number of important factors could cause actual
results to differ materially from those contained in any
forward-looking statement. The Company does not undertake any
obligation to update any forward-looking statement, except as
required under applicable law.
View original
content:http://www.prnewswire.com/news-releases/concord-medical-announces-a-hoisting-ceremony-for-the-proton-therapy-system-of-guangzhou-concord-cancer-center-301142090.html
SOURCE Concord Medical Services Holdings Limited